Winstrol, Buy winstrol, Winstrol side effects
winstrolheader
Home      |        Services      |       Resources      |       Site Map      |       Contact Us
MENU
icon Winstrol
icon Winstrol side effects
icon Winstrol steroid
icon Oral winstrol
icon Winstrol for woman
icon Winstrol dosage
   
  Featured Links
 
icon Anabolic Steroids
icon Buy Steroids
icon Buy Steroids
icon Steroid Abuse
   
Winstrol dosage:
Alot of what holds true for the injectable version of this product (see: Winstrol Depot) also holds for the tabs. There are, however, two noticable differences between the two forms of administration. Nitrogen Retention is greater with use of the injectable version, when equal doses are administered. Paradoxically, it would seem that on a milligram for milligram basis, users have reported that oral administration of Stanozolol was more potent than the injectable produc for building muscle. This could be due to winstrol's ability to lower SHBG (Sex Hormone Binding Globulin) levels and also elevate IGF (Insulin-Like Growth Factor) above those experienced with the injectable version.

British Dragon winstrol tabs are one of the most popular versions on the market today. Women athletes commonly reported the use of Stanozolol at a dosage of 10mg daily, and I am of the opinion that women should preferentially use the injectable version when possible.
Men have found that it works well when used in 50-100mg daily doses, and stacked very efficiently with Testosterone and Nandrolone or Trenbolone.

Reported Characteristics:
Pharmaceutical Name:Stanozolol Chemical Name:17-beta-hydroxy-17-methyl-5alpha-androstano[3,2-c]pyrazole Cutting/Bulking:Cutting Anabolic Rating:320 Active-Life: About 8 hours Drug Class: Anabolic/Androgenic steroid (Oral) Average Reported Dosage: Males 25-50-mg daily Women 10mg daily Acne: Possible Water Retention: No High Blood Pressure: Rare Liver Toxic: High in high oral dosages DHT Conversion: DHT-derived Decreases HPTA Function: No Average Price:Up to $1/10mg tab

 
Provectus Lead Investigator Professor John F. Thompson to Present at Clinical Oncological Society of Australia 2008 Annual Scientific Meeting on November 19, 2008
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), development-stage oncology and dermatology biopharmaceutical company, announced that the lead investigator for its Phase 2 melanoma study, Professor John F. Thompson,...


Research Provides Further Evidence for the Mechanism of Action Underlying Hythiam’s Prometa Treatment Program
PROMETA Reverses GABA Receptor Dysregulation in Methamphetamine Dependent Rats with Increased Anxiety During Withdrawal LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM), announced today the presentation of data further supporting a...


New Data Will Be Presented at ASH on Velcade (Bortezomib) for Injection-Based Therapies in Multiple Myeloma and Non-Hodgkin's Lymphoma
CAMBRIDGE, Mass., November 18, 2008 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced that 120 data presentations concerning VELCADE research will be featured at the 50th American Society of Hematology (ASH) Annual Meeting in...


New Publication Shows Angiomax Significantly Reduces Initial Hospital Costs by $572 Per Patient Compared to Conventional Therapy in Moderateand High-Risk ACS Patients
Prospective Economic Evaluation of Alternative Antithrombotic Strategies Published in the Journal of the American College of Cardiology Intended for U.S. Audiences Only PARSIPPANY, N.J, Nov. 18, 2008--(BUSINESS WIRE)--The Medicines Company (NASDAQ:...


XTL Biopharmaceuticals Announces Top-Line Results From the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain
Study failed to meet its primary endpoint VALLEY COTTAGE, N.Y., November 18, 2008 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic...


Metabolex Announces Positive Results from Phase 2 Clinical Trial of MBX-8025
Compound Significantly Improves Multiple Lipid and Metabolic Parameters HAYWARD, Calif., November 18, 2008 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the...


Study Published In Archives Of Surgery Demonstrated Benefit Of Entereg (Alvimopan) In Postoperative Ileus
 Study Reports that ENTEREG(R) Accelerated GI Recovery and Shortened Length of Stay in Patients Undergoing Partial Small or Large Bowel Resection with Primary Anastomosis - EXTON, Pa. & PHILADELPHIA, Nov 18, 2008 (BUSINESS WIRE) -- Adolor...


Company's MPACs for the Treatment of Alzheimer's Disease Shown to Prevent Neural Cell Death and the Production of Amyloid-Beta Protein
MELBOURNE, Australia - November 18, 2008: Prana Biotechnology Limited (NASDAQ: PRAN / ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that a recent...


Cimzia (certolizumab pegol) Studies Show Significant Clinical Benefits for Mono- and Combination Therapy in Patients with Rheumatoid Arthritis
•         FAST 4WARD showed monotherapy CIMZIA® 400 mg, dosed every four weeks, provided significant clinical benefits compared to placebo •         RAPID...


Long-Term TITAN Study Evaluates Prezista/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
BRIDGEWATER, N.J., November 18, 2008 /PRNewswire/ -- Tibotec recently announced long-term study results from a phase 3 clinical trial, which compared PREZISTA (darunavir)/ritonavir to lopinavir/ritonavir, as part of HIV combination therapy, in...


ARYx Therapeutics Presents Clinical Data for ATI-5923 at American Heart Association Scientific Sessions 2008
Novel Oral Anticoagulant Promises Potential Benefits over Leading Treatment AHA Scientific Sessions 2008 NEW ORLEANS--(BUSINESS WIRE)--ARYx Therapeutics (NASDAQ:ARYX) announced today that clinical data for ATI-5923, a novel vitamin K epoxide...


Biodel Reports Protective Effects of VIAject Insulin on Microvascular Function in Patients with Type 2 Diabetes
DANBURY, Conn.--(BUSINESS WIRE)--Biodel Inc. (Nasdaq: BIOD) today reported positive effects of VIAject™ insulin on microvascular function in patients with Type 2 diabetes which were superior to results seen with regular human insulin and...


Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7%
Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using...


ZIOPHARM Oncology Presents Positive Data from Studies of Palifosfamide
Palifosfamide active as single agent and in combination LONDON--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it presented positive data from a Phase I study of palifosfamide (ZymafosTM) in combination with doxorubicin...


Patients Experienced Nearly a 70% Reduction in Pain When Using MPMMedical's Regenecare Wound Care Gel
Regenecare Continues to Garner Clinical Acclaim IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences (OTCBB:RBCL) — A recent clinical study found that patients experienced nearly a 70% reduction in pain when MPM Medical Inc.’s Regenecare...


Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
    ROCKVILLE, Md., November 17, 2008 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat infectious diseases of epidemic potential, announces the successful demonstration...


Paloma Pharmaceuticals Publishing Seminal Paper in Cancer Research and Presentation at the AACR Special Conference in Cancer Research
- Presentations highlight Palomid 529 as a first-in-class dual TORC1/TORC2 inhibitor - JAMAICA PLAIN, Mass., November 17, 2008 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. today announced the publication of a first and seminal paper describing the...


Medivation Announces Upcoming Data Presentations on Dimebon's Mechanism of Action
SAN FRANCISCO, November 17, 2008 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that new data about the mechanism of action of Dimebon, its lead product candidate in development to treat Alzheimer's and Huntington's diseases, will be...


Alkermes Presents Positive Preclinical Data on Novel, ProprietaryMolecule Designed to Improve Outcomes for Patients Taking OpioidAnalgesics
Second New Program Disclosed During Calendar 2008 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced positive preclinical results for its proprietary small molecule candidate, RDC-1036, which emerged from a library of...


FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
Preliminary Analysis Demonstrates an 11-Meter Improvement in Six-Minute Walk Distance at Week 16 (p=0.072) SILVER SPRING, Md., Nov. 17 /PRNewswire-FirstCall/ -- United Therapeutics Corporation announced today the results of the FREEDOM-C trial of...


New Data Points to Long Lasting Beneficial Effects of CEL-SCI's Rheumatoid Arthritis Vaccine
VIENNA, Va., November 14, 2008 /PRNewswire-FirstCall/ -- CEL-SCI Corporation announced today the presentation of new rheumatoid arthritis data at the 6th annual GTCbio Vaccine Conference in Vienna, Va. The data, presented by Dr. Daniel Zimmerman,...


Oramed Pharmaceuticals Presents Results of Oral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs
The Study Suggests That the GLP-1 Analog Exenatide -4 When Combined With Oramed's Absorption Promoters is Absorbed Through the Gastrointestinal Tract and Retains its Biological Activity JERUSALEM, Israel, November 14, 2008 /PRNewswire-FirstCall/ --...


Oxford BioMedica Announces Two Scientific Presentations of ProSavin in Parkinson's Disease
– 16th Annual Congress of European Society of Gene and Cell Therapy – – 38th Annual Meeting of Society for Neuroscience – Oxford, UK – 14 November 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company,...


Oncolytics Biotech Inc. Collaborators to Present Reolysin Research at CTOS Annual Meeting
CALGARY, November 14, 2008 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. announced today that a poster presentation authored by Dr. Anders Kolb of the Nemours Center for Childhood Cancer Research entitled "Systemic Administration of REOLYSIN...


ThromboGenics Announces Promising Six Month Follow-Up Results from its Phase IIb Trial of Microplasmin (MIVI III) for Treatment of Visual Disorders
  - Results Continue to Support Microplasmin's Potential to Make a Major Contribution to the Treatment of Back of the eye Disease LEUVEN, Belgium, November 14, 2008 /PRNewswire-FirstCall/ --ThromboGenics NV , a biotechnology company focused on...


Avastin Gives an Additional Four Months of Life to Patients with One of the Most Common Types of Lung Cancer
Phase III trial shows patients with advanced adenocarcinoma of the lung have a 45%  better chance of survival with Avastin BASEL, Switzerland, 13 November 2008--Roche announced today that an exploratory analysis of the pivotal phase III E4599...


BioReliance Corporation Announces that Sarah Sheridan, Ph.D. Will Deliver a Poster Presentation at the 16th Annual European Society of Gene and Cell Therapy Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--Nov 13, 2008 - BioReliance Corporation announced today that Dr. Sarah Sheridan, a Scientific Director in BioReliance's Glasgow, Scotland, facility, will deliver a poster presentation regarding her work in gene...


ViroPharma Announces Presentation of Cinryze Data in Acute Treatment of Hereditary Angioedema
- New Data from Open Label Study and New Data Suggesting Need for Improved HAE   Screening Presented at ACAAI 2008 Annual Meeting - EXTON, Pa., Nov. 12 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the...


Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months...


Preclinical Study Presented at the International Congress of Endocrinology Shows Intravail Drug Delivery Technology Provides Unmatched Non-Invasive Delivery of an Anti-Obesity Peptide
SAN DIEGO, Nov. 12, 2008/MarketWire/  Aegis Therapeutics LLC announced today that preclinical data was presented at the 2008 International Congress of Endocrinology in Rio de Janeiro, Brasil  demonstrating that its Intravail®...


Seniors Can Be Heartened by New Study on Statins
    RESTON, Va., November 13, 2008 /PRNewswire-USNewswire/ -- Cardiovascular Disease is the leading cause of death among Americans, costing our healthcare system hundreds of millions of dollars and causing untold suffering. Now there is new hope...


Scientists Crack the Code to Tamoxifen Resistance
LONDON, Nov. 13, 2008--Cancer Research UK scientists have discovered the molecular basis for tamoxifen response in breast cancer cells - and the reason why some women can develop resistance to the treatment, according to a study published in...


Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
    SAN DIEGO, November 13, 2008 /PRNewswire/ -- Ambrx Inc. today announced Phase I/II clinical trial data demonstrating that ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono,...


Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Nov 13, 2008 - GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant), the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external...


Micromet to Present Interim Data from Two Studies for T Cell Engaging BiTE Antibody Blinatumomab at American Society of Hematology Annual Meeting
BETHESDA, Md., November 13, 2008 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that two studies on...


Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences
MELBOURNE, Australia--(BUSINESS WIRE)--Nov. 13, 2008 - Australian biotechnology company Avexa (ASX:AVX) today announced the presentation of 48 week data from its apricitabine program at the Ninth International Congress on Drug Therapy in HIV...


Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Pivotal Study Evaluating Efficacy of GARDASIL in Males in Preventing HPV 6, 11, 16 and 18-Related External Genital Lesions   WHITEHOUSE STATION, N.J., Nov. 13, 2008 - GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18)...


Osteoporosis Drugs May Prevent Future Bone Growth
(BUSINESS WIRE)--Nov 13, 2008 - Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced...


Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Successfully Completes Phase 1 Clinical Trials
 * Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid  Patients * Potent Reduction in Serotonin Achieved *Drug Candidate Being Developed Under Fast Track Status From FDA THE WOODLANDS, Texas, Nov. 13, 2008 (GLOBE NEWSWIRE) --...


MorphoSys Publishes Preclinical Data from MOR103 Program
Antibody Shows Ability to Inhibit Disease in an Established RA Model Martinsried/Munich, Germany, November 13, 2008 - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced...


Home    |    Services   |    Resources    |    Site Map   |    Contact Us
Copy rights reserved by iwinstrol.com